Induction of fibronectin by HER2 overexpression triggers adhesion and invasion of breast cancer cells

被引:37
|
作者
Jeon, Myeongjin [1 ,2 ]
Lee, Jeongmin [1 ]
Nam, S. J. [1 ]
Shin, Incheol [3 ]
Lee, J. E. [1 ,2 ]
Kim, Sangmin [1 ]
机构
[1] Samsung Med Ctr, Dept Surg, Seoul 135710, South Korea
[2] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul 135710, South Korea
[3] Hanyang Univ, Dept Life Sci, Seoul 133791, South Korea
关键词
Fibronectin; HER2; Trastuzumab; Adhesion; Invasion; MESENCHYMAL TRANSITION; ADJUVANT CHEMOTHERAPY; EXPRESSION; TRASTUZUMAB; KINASE; GROWTH; EGF; ONCOGENE; THERAPY; PATHWAY;
D O I
10.1016/j.yexcr.2015.02.019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fibronectin (FN), an extracellular matrix ligand, plays a pivotal role in cell adhesion, migration, and oncogenic transformation. Aberrant FN expression is associated with poor prognoses in various types of cancer, including breast cancer. In the current study, we investigated the relationship between FN induction and HER2 expression in breast cancer cells. Our results showed that the level of FN expression increased in response to HER family ligands, EGF and TGF-alpha in a time- and dose-dependent manner. On the other hand, EGF-induced FN expression decreased in response to trastuzumab, which is a HER2-targeted monoclonal antibody. However, EGF-induced FN expression was not affected by trastuzumab in JIMT-1 breast cancer cells, which are trastuzumab insensitive cells. Next, we introduced the HER2 gene into MDA-MB231 cells to verify the relationship between FN and HER2. The level of FN expression significantly increased in HER2-overexpressed MDA-MB231 cells. In contrast, the induction of FN by HER2 was significantly decreased in response to trastuzumab treatment. In addition, the induction of FN by HER2 was down-regulated by the MEK 1/2 specific inhibitor, U0126. Using conditioned culture media of vec- and HER2-overexpressed MDA-MB231 cells, we observed the cell morphology, adhesion, and invasion of MDA-MB231 cells. Interestingly, in conditioned culture media of HER2-overexpressed MDA-MB231 cells, the cell morphology was altered, and adhesion and invasion of MDA-MB231 cells significantly increased. In addition, our results showed that recombinant human FN augmented cell adhesion and invasion of MDA-MB231 cells while these inductions decreased in response to an FN inhibitor. Therefore, we demonstrated that the induction of FN by HER2 triggers cell adhesion and invasion capacities. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:116 / 126
页数:11
相关论文
共 50 条
  • [41] Standardized Assessment of the HER2 Status in Breast Cancer by Immunohistochemistry
    Hicks, David G.
    LABMEDICINE, 2011, 42 (08): : 459 - 467
  • [42] HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
    Lee, Hee Jin
    Seo, An Na
    Kim, Eun Joo
    Jang, Min Hye
    Suh, Koung Jin
    Ryu, Han Suk
    Kim, Yu Jung
    Kim, Jee Hyun
    Im, Seock-Ah
    Gong, Gyungyub
    Jung, Kyung Hae
    Park, In Ae
    Park, So Yeon
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 142 (06) : 755 - 766
  • [43] HER2 testing in patients with breast cancer
    Dixon, J. Michael
    Wilson, Victoria
    Verrill, Mark
    Symmans, W. Fraser
    BMJ-BRITISH MEDICAL JOURNAL, 2012, 344
  • [44] Biological and clinical significance of HER2 overexpression in breast cancer
    Kurebayashi J.
    Breast Cancer, 2001, 8 (1) : 45 - 51
  • [45] HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib
    Valabrega, Giorgio
    Capellero, Sonia
    Cavalloni, Giuliana
    Zaccarello, Gianluca
    Petrelli, Annalisa
    Migliardi, Giorgia
    Milani, Andrea
    Peraldo-Neia, Caterina
    Gammaitoni, Loretta
    Sapino, Anna
    Pecchioni, Carla
    Moggio, Aldo
    Giordano, Silvia
    Aglietta, Massimo
    Montemurro, Filippo
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 130 (01) : 29 - 40
  • [46] Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer
    Blok, Erik J.
    Kuppen, Peter J. K.
    van Leeuwen, Jeroen E. M.
    Sier, Cornelis F. M.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2013, 7 : 41 - 51
  • [47] HER2 Mutation Status in Japanese HER2-negative Breast Cancer Patients
    Endo, Yumi
    Dong, Yu
    Yoshimoto, Nobuyasu
    Asano, Tomoko
    Hato, Yukari
    Yamashita, Hiroko
    Sato, Shinya
    Takahashi, Satoru
    Fujii, Yoshitaka
    Toyama, Tatsuya
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (07) : 619 - 623
  • [48] Quantitative diagnosis of HER2 protein expressing breast cancer by single-particle quantum dot imaging
    Miyashita, Minoru
    Gonda, Kohsuke
    Tada, Hiroshi
    Watanabe, Mika
    Kitamura, Narufumi
    Kamei, Takashi
    Sasano, Hironobu
    Ishida, Takanori
    Ohuchi, Noriaki
    CANCER MEDICINE, 2016, 5 (10): : 2813 - 2824
  • [49] Precision HER2: a comprehensive AI system for accurate and consistent evaluation of HER2 expression in invasive breast Cancer
    Xiong, Zhongtang
    Liu, Kai
    Liu, Shaoyan
    Feng, Jiahao
    Wang, Jin
    Feng, Zewen
    Lai, Boan
    Zhang, Qingxin
    Jiang, Qingping
    Zhang, Wei
    BMC CANCER, 2024, 24 (01)
  • [50] HER2 breast cancer therapies: a review
    Murphy, Conleth G.
    Modi, Shanu
    BIOLOGICS-TARGETS & THERAPY, 2009, 3 : 289 - 301